Loading…
← CockpitCompetitor Analysis › 300016.SZ Beijing Beilu Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Beijing Beilu Pharmaceutical Co., Ltd. Class A300016.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum neutral 54
Mkt cap
$641M
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$28.5M
20-day average traded
Fwd P/E
79.7×
forward earnings
ROIC−WACC
-0.3 pp
WACC 6.9%
Hurdle
+1 pp
Req g minus delivered
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥7.24
1D-2.2%
1W-10.6%
1M-10.7%
3M-17.3%
6M-19.0%
YTD-8.8%
1Y-17.5%
ATR %4.8%
52w lowhigh36.4% off high

What Beijing Beilu Pharmaceutical does

Employees: 1,188

Beijing Beilu Pharmaceutical at a glance

Size Beijing Beilu Pharmaceutical (300016.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $641M, the 3093rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.24 on 18 Nov 2026.

Performance Over six months the shares fell 19.0%, against -17.5% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 23.5% over the last twelve months (peer median +10.5%); the operating margin is 10.7% (peer median 9.2%).

Valuation It trades at 79.7× forward earnings against a peer median of 24.9× (3rd most expensive of 8).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.3 points below its cost of capital (6.9% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 86300016.SZ 81
Six months, rebased to 100: Beijing Beilu Pharmaceutical against the median of its 20 peers (local-currency closes).

Beijing Beilu Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.39BCN¥1.20BCN¥977MCN¥886MCN¥760M
Revenue growth—+23%+10%+17%—
Gross profitCN¥642MCN¥513MCN¥428MCN¥382MCN¥385M
EBITDAn/aCN¥182MCN¥150MCN¥63.0MCN¥94.6M
Net incomeCN¥162MCN¥92.7MCN¥13.7M-CN¥71.8MCN¥11.3M
Free cash flowCN¥102M-CN¥42.0MCN¥74.8M-CN¥82.1MCN¥37.4M
Capital expenditureCN¥141MCN¥219MCN¥101MCN¥145MCN¥103M
Total debtCN¥531MCN¥607MCN¥881MCN¥822MCN¥701M

Quarterly statements and history in the cockpit →

Beijing Beilu Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-40%-20%0%0005664123INNOVACAP300878ABUSFDCBCAXSPARC301211OLMA4105ORCHPHARMA300194002940ANNX688488PHIL603567688658300016.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Beilu Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%+300%0×50×100×INNOVACAP4105ORCHPHARMA688488PHIL603567688658300016.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Beilu Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%4123INNOVACAPFDC4105300194002940688488603567300016.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Beijing Beilu Pharmaceutical is the large dot.

Beijing Beilu Pharmaceutical competitors and peer comparison

How Beijing Beilu Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Beilu Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300016.SZPeer medianRank in peer set
1-month return-10.7%-8.1%9th lowest of 20
6-month return-19.0%-17.5%9th lowest of 20
Distance from 52-week high-36.4%-41.0%10th highest of 20
Revenue growth (TTM)+23.5%+10.5%6th highest of 17
Operating margin10.7%9.2%7th highest of 16
Forward P/E79.7×24.9×3rd most expensive of 8
Growth the price implies (Req g, 7 yrs)9.1%18.1%2nd least demanding of 9
Growth delivered (Del g)+7.9%+9.6%4th lowest of 9
Hurdle (Req g minus delivered)+1.2 pp+13.5 pp3rd least demanding of 9
ROIC minus cost of capital-0.3 pp-4.1 pp4th highest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%79.7×9.1%+7.9%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%n/an/an/a
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%n/a36.3%+16.2%
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%32.2×27.1%+31.4%
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%n/an/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%n/an/an/a
FDC FDC.NSIndia$653M+3%+10%14%n/a25.2%+10.3%
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%n/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%n/an/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%10.2×-8.7%+8.8%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%83.1×n/an/a
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%n/a10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%n/a10.1%+2.1%
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%112.1×31.9%+19.8%
Philogen PHIL.MIItaly$672M-11%+295%79%10.1×n/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a5.4×9.1%-25.1%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%24.9×n/an/a

Questions

Which companies are Beijing Beilu Pharmaceutical's closest peers?
The cockpit's peer set: Hainan Haiyao (000566.SZ), Center Laboratories (4123.TWO), Innova Captab (INNOVACAP.NS), Zhejiang Wecome Pharmaceutical (300878.SZ), Arbutus Biopharma (ABUS), FDC (FDC.NS), Bicara Therapeutics (BCAX), Sun Pharma Advanced Research (SPARC.NS).
Is Beijing Beilu Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 79.7× against a peer median of 24.9×, 3rd most expensive of 8 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Beijing Beilu Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -19.0% against -17.5% for the median peer; over one year -17.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.